Survival analyses are a group of statistical principles applied to accurately analyze
the length of time until a previously defined event occurs. Increasing survival is
the underlying goal for most medical interventions, and is particularly critical in
oncology-related surgical fields. In order to justify the application of a novel surgical
intervention or other cancer therapy, one must first definitively show improvements
in patient survival compared to the existing method of treatment. In order to definitively
recommend one treatment option over another, it is paramount to design a study that
addresses and minimizes sources of bias where possible. This can be challenging due
to numerous factors including selecting an appropriate study design, dealing with
censored data, obtaining an appropriate sample size, and performing robust statistical
analysis. It is critical for surgeons in every stage of training to be able to both
understand and apply these methods in order to improve patient care. In this review,
we discuss approaches to design survival studies, relevant errors/biases, and how
to account for them and cover several field-standard methods to analyze survival data
including Kaplan-Meier plots, the log-rank test, and Cox Proportional Hazards Models.
Importantly, this is accompanied by easily repurposable examples of how to implement
these analyses in both R and GraphPad Prism using a publicly available survival dataset.
This review will assist surgeons of all training levels in the design and analysis
of survival studies and serve as a starting point for advancing patient care.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Seminars in Thoracic and Cardiovascular SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
The R Project for Statistical Computing. [cited 19 Sep 2021]. Available: https://www.r-project.org/
Home - GraphPad. [cited 19 Sep 2021]. Available: https://www.graphpad.com/
- Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.N Engl J Med. 2020; 383: 1711-1723
- Post-treatment mortality after surgery and stereotactic body radiotherapy for early-stage non-small-cell lung cancer.J Clin Oncol. 2018; 36: 642-651
- Survival probabilities (the Kaplan-Meier method).BMJ. 1998; 317: 1572
- Sample size estimation and power analysis for clinical research studies.J Hum Reprod Sci. 2012; 5: 7-13
- A practical guide to understanding Kaplan-Meier curves.Otolaryngol Head Neck Surg. 2010; 143: 331-336
- The log-rank test.BMJ. 2004; 328: 1073
- Regression models and life-tables.J Royal Stats Soc Series B (Methodological). 1972; 34: 187-202https://doi.org/10.1111/j.2517-6161.1972.tb00899.x
- Introduction to the analysis of survival data in the presence of competing risks.Circulation. 2016; 133: 601-609https://doi.org/10.1161/circulationaha.115.017719
- Biostatistics primer: what a clinician ought to know: hazard ratios.J Thorac Oncol. 2011; 6: 978-982
- Hazard ratio in clinical trials.Antimicrob Agents Chemother. 2004; 48https://doi.org/10.1128/AAC.48.8.2787-2792.2004
- How does multiple testing correction work?.Nat Biotechnol. 2009; 27: 1135-1137
Article info
Publication history
Published online: January 26, 2022
Footnotes
Disclosures: No disclosures relevant to this manuscript.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.